spacer
home > pmps > winter 2001 > developments in the biotechnology and pharmaceutical sectors
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Developments in the biotechnology and pharmaceutical sectors

Perhaps you can begin by giving a brief
overview of your company?

Avecia was formed in July 1999, following completion of a US$2.1 billion (£1.3 billion) buyout of the former Zeneca Specialties business from AstraZeneca. The deal was financed by Cinven and Investcorp - two of Europe's leading financial investment firms.

With sales of £700 million in 2000 and earnings of over £150 million, Avecia is one of Europe's leading and most profitable speciality chemical companies.

Avecia businesses are linked by common scientific and technical capabilities and are focused on delivering service to customers across a wide range of industries including health care, agrochemicals, coatings, graphic arts, leather imaging, mining, plastics, biotechnology, inks and automotive. The company has 4,700 employees and operates in the UK, US, Europe and the Far East.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Patricia Lobo, Editor of PMPS
John Blackie is currently the General Manager of Manufacturing for Pharmaceuticals and Biotechnology at Avecia. He is based in Scotland with accountability for manufacturing in Grangemouth in Scotland, Huddersfield in West Yorkshire and Billingham Teeside in north-east England. John graduated in chemical engineering from the University of Edinburgh.

After a few years in plant design and development, he entered manufacturing management. John has held a
variety of posts in site and operations management over 20 years within the ICI, Zeneca and most recently, Avecia groups. He has been a Senior Manager responsible for manufacturing in the UK for nine years and has spent two and a half years running Syngenta's (formerly Zeneca's) Belgian operations.


spacer
Patricia Lobo
spacer
spacer
spacer
John Blackie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement